Genes Tech Group Holdings Company Limited
Genes Tech Group Holdings Company Limited Fundamental Analysis
Genes Tech Group Holdings Company Limited (8257.HK) shows weak financial fundamentals with a PE ratio of 29.01, profit margin of 3.49%, and ROE of 4.01%. The company generates $1.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 33.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 8257.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak8257.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate8257.HK shows balanced valuation metrics.
Growth Score
Moderate8257.HK shows steady but slowing expansion.
Financial Health Score
Excellent8257.HK maintains a strong and stable balance sheet.
Profitability Score
Weak8257.HK struggles to sustain strong margins.
Key Financial Metrics
Is 8257.HK Expensive or Cheap?
P/E Ratio
8257.HK trades at 29.01 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 8257.HK's PEG of 0.43 indicates potential undervaluation.
Price to Book
The market values Genes Tech Group Holdings Company Limited at 1.12 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.91 times EBITDA. This is generally considered low.
How Well Does 8257.HK Make Money?
Net Profit Margin
For every $100 in sales, Genes Tech Group Holdings Company Limited keeps $3.49 as profit after all expenses.
Operating Margin
Core operations generate 13.47 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.01 in profit for every $100 of shareholder equity.
ROA
Genes Tech Group Holdings Company Limited generates $1.34 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genes Tech Group Holdings Company Limited produces operating cash flow of $159.20M, showing steady but balanced cash generation.
Free Cash Flow
Genes Tech Group Holdings Company Limited generates strong free cash flow of $154.94M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.15 in free cash annually.
FCF Yield
8257.HK converts 15.59% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
29.007
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.12
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.01
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.67
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.36
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How 8257.HK Stacks Against Its Sector Peers
| Metric | 8257.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 29.01 | 33.61 | Better (Cheaper) |
| ROE | 4.01% | 1020.00% | Weak |
| Net Margin | 3.49% | -56528.00% (disorted) | Weak |
| Debt/Equity | 0.67 | 0.45 | Weak (High Leverage) |
| Current Ratio | 1.36 | 5.65 | Neutral |
| ROA | 1.34% | -291484.00% (disorted) | Weak |
8257.HK outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genes Tech Group Holdings Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Growth, Innovation, High Beta
EPS CAGR
N/A
Industry Style: Growth, Innovation, High Beta
FCF CAGR
N/A
Industry Style: Growth, Innovation, High Beta